Summary
We compared the immunity induced by tumor cells modified with UV-inactivated purified vaccinia virus (UV-VV) and with live purified vaccinia virus (L-VV). C3H/HeN mice were inoculated i.p. with UV-VV or L-VV after whole-body irradiation with 150 rads of X-rays (priming). After 3 weeks the mice were immunized i.p. 3 times at weekly intervals with syngeneic X5563 or MH134 cells that had been adsorbed in vitro with UV-VV or infected with L-VV and subsequently irradiated with 104 rads of X-rays. Then 1 week after the last immunization, the mice were challenged s.c. with X5563 viable tumor cells or challenged i.p. with MH134 viable tumor cells. The 50% lethal dose (TLD50) of X5563 in mice primed and immunized with UV-VV (UV-VV group) on s.c. challenge (106.06) was the same as for mice treated with L-VV (L-VV group), whereas the TLD50 of unprimed or nonimmunized mice (control group) was 102.61. The TLD50 of MH134 in the UV-VV treated group on i.p. challenge (106.48) was similar to that of the L-VV treated group (106.54), while the TLD50 of the control group was 101.00. The difference between the TLD50 values of X5563 on s.c. challenge of mice primed and immunized with UV-VV or L-VV and control mice was 103.4. The difference between the TLD50 values of MH134 on i.p. challenge of primed and immunized mice and control mice was 105.5. These results indicate that the in vivo helper function of UV-VV is similar to that of L-VV and that the augmenting effect of this protocol depends on the kind of tumor.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ada GL, Jackson DC, Blauden RV, Tha Hla R, Bowern NA (1976) Changes in the surface of virus-infected cells recognized by cytotoxic T cells. Scand J Immunol 5:23
Boone CW, Blackman K (1972) Augmented immunogenicity of tumor cell homogenates infected with influenza virus. Cancer Res 32:1018
Chang A, Metz DH (1976) Further investigations on the mode of entry of vaccinia virus into cells. J Gen Virol 32:275
Currie GA, Bagshawe KD (1969) Tumor specific immunogenicity of methylcholanthrene-induced sarcoma cells after incubation in neuraminidase. Br J Cancer 23:141
Fujiwara H, Hamaoka, T, Shearer GM, Yamamoto H, Terry WD (1980) The augmentation of in vitro and in vivo tumorspecific T cell mediated immunity by amplifier T lymphocytes. J Immunol 124:863
Galili N, Naor D, Asjo B, Klein G (1976) Induction of immune responsiveness in a genetically low-responsive tumor host combination by chemical modification of the immunogen. Eur J Immunol 6:473
Hamaoka T, Fujiwara H, Teshima K, Aoki H, Yamamoto H, Kitagawa M (1979) Regulatory functions of hapten-reactive helper and suppressor T lymphocytes. III. Amplification of a generation of tumor-specific killer T lymphocytes. J Exp Med 149:185
Hosokawa M, Okayasu T, Ikeda K, Katoh H, Suzuki Y, Kobayashi H (1983) Alteration of immunogenicity of xenogenized tumor cells in syngeneic rats by the immune responses to virus-associated antigens produced on immunizing cells. Cancer Res. 43:2301
Ikuta K, Miyamoto H, Kato S (1978) Studies on the polypeptides of pox-virus I. Comparison of structural polypeptides in vaccinia, cowpox and shope fibroma viruses. Biken J 21:51
Joklik WK (1962) The purification of four strains of poxvirus. Virology 18:9
Kataoka T, Oh-Hashi F, Tsukagoshi S, Sakurai Y (1977) Induction of resistance to L1210 leukemia in BALB/c × DBA/2Cr F1 mice, with L1210 cells treated with glutaraldehyde and concanavalin A. Cancer 37:964
Klein G (1966) Tumor antigens. Annu Rev Microbiol 20:233
Kobayashi H, Sendo F, Shirai T, Kaji H, Kodama T, Saito H (1969) Modification in growth of transplantable rat tumors exposed to Friend virus. J Natl Cancer Inst 42:413
Lindenmann J (1965) Immunity to transplantable tumors following viral oncolysis. I. Mechanism of immunity of Ehrlich ascites tumors. J Immunol 94:461
Lindenmann J, Klein PA (1967) Viral oncolyis: Increased immunogenicity of host cell antigen associated with influenza virus. J Exp Med 126:93
Martin WJ, Wunderlich JR, Fletcher F, Inman JK (1971) Enhanced immunogenicity of chemically-coated syngeneic tumor cells. Proc Natl Acad Sci USA 68:469
Martin WJ, Esber E, Wunderlich JR (1973) Evidence for the suppression of the development of cytotoxic lymphoid cells in tumor immunized mice. Fed Proc 32:173
Mitchison NA (1970) Immunologic approach to cancer. Transplant Proc 2:92
Miyamoto H, Kato S (1968) Immune hemadsorption by cells infected with poxviruses. Biken J 11:343
Miyamoto H, Kato S (1971) Cell surface antigens induced by poxviruses. I. Effects of antimetabolites on cell surface antigens. Biken J 14:311
Oie M, Ichihashi Y (1981) Target antigen of vaccinia-infected cells recognized by virus-specific cytotoxic T lymphocytes. Microbial Immunol 25:361
Payne LG, Norrby E (1976) Presence of hemagglutinin in the envelope of extracellular vaccinia virus particles. J Gen Virol 32:63
Reed LJ, Muench HA (1938) A simple method of estimating fifty per cent endpoints. Am J Hyg 27:493
Shimizu Y, Fujiwara H, Ueda S, Wakamiya N, Kato S, Hamaoka T (1984) The augmentation of tumor-specific immunity by virus help II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus-reactive helper T cells. Eur J Immunol 14:839
Takatsu K, Hamaoka T, Tominaga A, Kanemasa Y (1980) Augmented induction of tumor-specific resistance by priming with Mycobacterium tuberculosis (Tbc) followed by the immunizations with PPD-coupled syngeneic tumor cells. J Immunol 125:2367
Ueda Y, Tagaya I (1973) Induction of skin resistance to vaccinia-soluble early antigens. J Exp Med 138:1033
Ueda Y, Tagaya I, Amano H, Ito M (1972) Studies on the early antigens induced by vaccinia virus. Virology 49:794
Ueda S, Wakamiya N, Wu K-S, Kato S, Fujiwara H, Hamaoka T (1984) Additional evidence for the augmented induction of tumor-specific resistance in vaccinia virus-primed mice by immunization with vaccinia virus-modulated syngeneic tumor cells. Biken J 27:1
Wallack MK (1981) Specific immunotherapy with vaccinia oncolysates. Cancer Immunol Immunother 12:1
Wallack MK, Steplewski Z, Koprowski H, Rosato E, George J, Hulihan B, Johnson J (1977) A new approach in specific, active immunotherapy. Cancer 39:560
Wu K-S, Ueda S, Sakaue Y, Ohashi Y, Ikuta K, Sugano T, Kato S (1981) Prevention of syngeneic tumor growth in vaccinia virus-primed mice by immunization with vaccinia virusmodulated tumor cells. Biken J 24:153
Yamaguchi H, Moriuchi T, Hosokawa M, Kobayashi H (1982) Increased or decreased immunogenicity of tumor-associated antigen according to the amount of virus-associated antigen in rat tumor cells infected with Friend virus. Cancer Immunol Immunother 12:119
Yoshioka T, Fukuzawa M, Takai Y, Wakamiya N, Uead S, Kato S, Fujiwara H, Hamaoka T (1986) The augmentation of tumor-specific immunity by virus-help III. Enhanced generation of tumor-specific Lyt-1 +2− T cells is responsible for augmented tumor immunity in vivo. Cancer Immunol Immunother (in press)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wakamiya, N., Wang, YL., Imai, H. et al. Feasibility of UV-inactivated vaccinia virus in the modification of tumor cells for augmentation of their immunogenicity. Cancer Immunol Immunother 23, 125–129 (1986). https://doi.org/10.1007/BF00199818
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00199818